Myasthenia Gravis Therapeutics Market Size, Share, Industry, Forecast and outlook (2024-2031)

Global Myasthenia Gravis Therapeutics Market is segmented By Type (Ocular myasthenia gravis, Congenital myasthenia gravis, Generalized myasthenia gravis, Transient myasthenia gravis, Others), By Treatment (Cholinesterase inhibitors, Immunosuppressive drugs, Plasmapheresis and intravenous immunoglobulin, Thymectomy, Other), By End-user (Hospital, Clinics, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031

Report Overview

The Global Myasthenia Gravis Therapeutics Market is expected to grow at a CAGR of 6% during the forecast period (2024-2031).

Myasthenia gravis is a long-term neuromuscular disease that leads to varying degrees of skeletal muscle weakness. Muscles of the eyes, face and swallowing are the most commonly affected muscles in the body. The weakening of these muscles can result in double vision, drooping eyelids, trouble talking, and trouble walking. Although a rare disease, the prevalence of the disease has increased over the past few decades, as per National Organization for Rare Disorders. As a result, the research and development in understanding the disease and finding a cure have also increased these factors have driven the growth of the market in the forecast period.

Myasthenia Gravis Therapeutics Market Summary

For More Insights Request Free Sample

Market Dynamics

The global myasthenia gravis therapeutics market growth is driven by the rising adoption of immunotherapies, the approval of promising drugs, the emergence of biologics, and increasing awareness of rare diseases.

Rising in the number of  myasthenia gravis cases is expected to drive the growth in the forecast period

According to the National Organization for Rare Disorders (NORD), in the U.S. around 14-40 per 100,000 individuals suffer from myasthenia gravis. Reports suggest that the frequency of the disorder is on the rise over the last several decades. This can be attributed to the better identification of patients and the increasing prevalence of autoimmune disorders in general across the world.

 Myasthenia gravis occurs more frequently in females than in males, and although symptoms may appear at any age, its onset usually peaks in men in their 50s or 60s and women during their 20s or 30s. There is no proven cure for myasthenia gravis, however, patients can be treated with medications and surgery for the management of the symptoms.

At present, research is focused on a better understanding of the specifics of the autoimmune problems associated with myasthenia gravis and improving their diagnosis and treatment. Additionally, the market is observing a paradigm shift in the area of research from suppressing the immune system to rebalancing it. Another important area of research is the physiology of the neuromuscular junction (NMJ), aimed at improvement in its function regardless of probable immune system attacks. These factor is driving the growth of the market in the forecast period.

Prevalence of Autoimmune Disorder, expected to drive the market growth

An autoimmune disorder is a condition of the immune system in which the body's immune system attacks healthy cells. It is most common in older men (over 60) and young adult women (under 40). Hence, an increase in the geriatric population is a key factor likely to boost the growth of the market. For instance, according to Cancer Facts & Figures 2019, the estimated number of older adults aged 85 years and above was 6.4 million in 2016 and it is expected to reach 19.0 million by 2060.

Myasthenia gravis (MG) is an autoimmune neuromuscular disorder that affects voluntary muscles. According to the Myasthenia Gravis Foundation of America, around 20 in 100,000 people in the U.S. are diagnosed with myasthenia gravis each year.

Side effects of available products are likely to hinder the market growth

On the contrary, side effects associated with intravenous immunoglobulin (IVIG) preparations could present serious health problems in some patients. Some of the side effects associated with intravenous immunoglobulin (IVIG) are flushing muscle cramps, chills, fever, nausea, vomiting, back/joint pain, chest pain, sudden cough, wheezing, or shortness of breath. These side effects can sometimes force a patient to discontinue the therapy which is leading to restraining the market.

COVID-19 Impact Analysis

During the COVID-19 pandemic patients with autoimmune myasthenia gravis, might be at greater risk of worse outcomes than otherwise healthy people because of an immunocompromised state related to immunotherapy and possible respiratory and bulbar muscular weakness. However, cessation of immunotherapy in neuroinflammatory disorders has severe risks as well. Moreover, infections are a well-recognised trigger of symptom exacerbation in patients with myasthenia gravis, and some drugs used in therapeutic trials early in the pandemic, including hydroxychloroquine and azithromycin, can provoke symptom exacerbations. COVID-19 Associated Risks and Effects in Myasthenia Gravis (CARE-MG), is a joint effort of the International MG/COVID-19 Working Group and neurologists who help to take care of patients with myasthenia gravis globally and was formally launched on April 9, 2020. All these factors will drive the growth of the market in the forecast period.

Market Segment Analysis

By treatment, the myasthenia gravis therapeutics market is classified into cholinesterase inhibitors, immunosuppressive drugs, plasmapheresis and intravenous immunoglobulin, thymectomy, others.

The immunosuppressive drugs, the segment is expected to grow at the fastest CAGR during the forecast period (2020-2027) 

Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body’s immune system. Some of these drugs are used to make the body less likely to reject a transplanted organ, such as a liver, heart, or kidney. With the rise in the number of organ transplants and the growing prevalence of autoimmune diseases worldwide, the global immunosuppressive drugs market is likely to gather momentum throughout the review. There has been a substantial rise in the number of organ transplants in recent years. Transplants for various organs such as the pancreas, liver, kidneys, and lungs are on the rise thereby supporting the growth opportunities for the global immunosuppressive drugs market. According to the findings of the World Health Organization (WHO), nearly 91,800 kidney transplant procedures, around 6,200 lung transplants and about 30,800 liver transplants took place in 2018. Prominent companies of the world are making efforts to leverage the rise in organ transplant procedures, which is likely to add to the growth of the market in times to come.

Cholinesterase inhibitors are growing at a fast rate in the forecast period. For instance, Rozanolixizumab (UCB7665) is a humanized anti-human neonatal Fc receptor (FcRn) monoclonal antibody designed to reduce the levels of pathogenic IgG in autoimmune diseases. It is in the clinical trial phase for reducing the levels of pathogenic IgG in autoimmune diseases and myasthenia gravis. Strong pipeline and introduction of new therapies are the factors likely to boost the growth of the myasthenia gravis market.

Based on application, the Myasthenia Gravis Therapeutics market is classified into dermatology, chemotherapy, ophthalmology, plastic surgery, and others.

Market Geographical Share

North America region holds the largest market share global Myasthenia Gravis Therapeutics market

North America is expected to hold a major market share in the global myasthenia gravis therapeutics market. According to Myasthenia Gravis Foundation of America 2019 data, the prevalence of myasthenia gravis in the United States is estimated at 14 to 20 per 100,000 population, which approximately translates to 36,000 to 60,000 cases in the United States. However, the report states that myasthenia gravis may be underdiagnosed in many cases and the prevalence might be higher. The report also suggests that women are more often affected than men. The most common age at onset is the 20s and 30s in women and the 60s and 70s in men. ​

However, the developed North American countries like the US and Canada have well-structured and developed healthcare systems. These countries also promote research and development for rare diseases and hence have very high expenditures on healthcare. As a result of these policies, many companies globally are encouraged to operate in this region.

Moreover, most of the population in developed countries like the US and Canada are covered under medical and health insurance and hence, can afford the expensive medication and therapies for myasthenia gravis. Hence, the North American region is expected to cover a large share of the myasthenia gravis market.

Market Companies and Competitive Landscape

The myasthenia gravis therapeutics market is moderately competitive with the presence of local as well as global companies.  Some of the key players which are contributing to the growth of the market include Alexion Pharmaceutical Inc., Grifols SA, Avadel Pharmaceuticals plc. Novartis AG, Pfizer, Inc., AbbVie Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline plc, Bausch Health Companies Inc., and Shire plc. Alexion Pharmaceuticals and Astellas Pharma among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the myasthenia gravis therapeutics market globally.    

Pfizer Inc. 

Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). IH focuses on developing and commercializing medicines and vaccines that improve patients' lives. IH therapeutic areas include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases. EH includes legacy brands, branded generics, generic sterile injectable products, biosimilars and infusion systems. EH also includes a research and development (R&D) organization, as well as its contract manufacturing business. The Company sold its products in over 125 countries.

Product Portfolio: The Company’s portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.